149 related articles for article (PubMed ID: 11976730)
1. Adoptive cancer immunotherapy: discovering the best targets.
Perreault C; Brochu S
J Mol Med (Berl); 2002 Apr; 80(4):212-8. PubMed ID: 11976730
[TBL] [Abstract][Full Text] [Related]
2. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease.
Fontaine P; Roy-Proulx G; Knafo L; Baron C; Roy DC; Perreault C
Nat Med; 2001 Jul; 7(7):789-94. PubMed ID: 11433342
[TBL] [Abstract][Full Text] [Related]
3. T cells targeted against a single minor histocompatibility antigen can cure solid tumors.
Meunier MC; Delisle JS; Bergeron J; Rineau V; Baron C; Perreault C
Nat Med; 2005 Nov; 11(11):1222-9. PubMed ID: 16227989
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of cancer through targeting of minor histocompatibility antigens.
Hambach L; Goulmy E
Curr Opin Immunol; 2005 Apr; 17(2):202-10. PubMed ID: 15766682
[TBL] [Abstract][Full Text] [Related]
5. Minor transplantation antigens: mouse models for human host-versus-graft, graft-versus-host and graft-versus-leukemia reactions.
Simpson E
Arch Immunol Ther Exp (Warsz); 1998; 46(6):331-9. PubMed ID: 9883311
[TBL] [Abstract][Full Text] [Related]
6. Minor histocompatibility antigens as targets of cellular immunotherapy in leukaemia.
Falkenburg JH; Willemze R
Best Pract Res Clin Haematol; 2004 Sep; 17(3):415-25. PubMed ID: 15498713
[TBL] [Abstract][Full Text] [Related]
7. Minors come of age: Minor histocompatibility antigens and graft-versus-host disease.
Chao NJ
Biol Blood Marrow Transplant; 2004 Apr; 10(4):215-23. PubMed ID: 15077220
[TBL] [Abstract][Full Text] [Related]
8. Targeting haematopoietic-specific minor histocompatibility antigens to distinguish graft-versus-tumour effects from graft-versus-host disease.
Spaapen R; Mutis T
Best Pract Res Clin Haematol; 2008 Sep; 21(3):543-57. PubMed ID: 18790454
[TBL] [Abstract][Full Text] [Related]
9. [Minor antigens - major impact. The role of minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation].
Hudecek M; Bartsch K; Tschiedel S; Niederwieser D
Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1511-6. PubMed ID: 18597211
[TBL] [Abstract][Full Text] [Related]
10. Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapy.
Spaapen R; van den Oudenalder K; Ivanov R; Bloem A; Lokhorst H; Mutis T
Clin Cancer Res; 2007 Jul; 13(13):4009-15. PubMed ID: 17606735
[TBL] [Abstract][Full Text] [Related]
11. Immunodominant minor histocompatibility antigens expressed by mouse leukemic cells can serve as effective targets for T cell immunotherapy.
Pion S; Fontaine P; Baron C; Gyger M; Perreault C
J Clin Invest; 1995 Apr; 95(4):1561-8. PubMed ID: 7706462
[TBL] [Abstract][Full Text] [Related]
12. Identification of an immunodominant mouse minor histocompatibility antigen (MiHA). T cell response to a single dominant MiHA causes graft-versus-host disease.
Perreault C; Jutras J; Roy DC; Filep JG; Brochu S
J Clin Invest; 1996 Aug; 98(3):622-8. PubMed ID: 8698852
[TBL] [Abstract][Full Text] [Related]
13. Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.
Feng X; Hui KM; Younes HM; Brickner AG
Trends Immunol; 2008 Dec; 29(12):624-32. PubMed ID: 18952501
[TBL] [Abstract][Full Text] [Related]
14. Minor histocompatibility antigens: targets for tumour therapy and transplant tolerance.
Spierings E
Int J Immunogenet; 2008 Aug; 35(4-5):363-6. PubMed ID: 18976439
[TBL] [Abstract][Full Text] [Related]
15. Haematopoietic cell transplantation as immunotherapy.
Appelbaum FR
Nature; 2001 May; 411(6835):385-9. PubMed ID: 11357147
[TBL] [Abstract][Full Text] [Related]
16. Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application.
Griffioen M; van Egmond HM; Barnby-Porritt H; van der Hoorn MA; Hagedoorn RS; Kester MG; Schwabe N; Willemze R; Falkenburg JH; Heemskerk MH
Haematologica; 2008 Oct; 93(10):1535-43. PubMed ID: 18768532
[TBL] [Abstract][Full Text] [Related]
17. Graft-versus-host disease associated T helper cell responses specific for minor histocompatibility antigens are mainly restricted by HLA-DR molecules.
van Els CA; Zantvoort E; Jacobs N; Bakker A; van Rood JJ; Goulmy E
Bone Marrow Transplant; 1990 Jun; 5(6):365-72. PubMed ID: 2142441
[TBL] [Abstract][Full Text] [Related]
18. T lymphocyte responses to multiple minor histocompatibility antigens generate both self-major histocompatibility complex-restricted and cross-reactive cytotoxic T lymphocytes.
Tremblay N; Fontaine P; Perreault C
Transplantation; 1994 Jul; 58(1):59-67. PubMed ID: 8036709
[TBL] [Abstract][Full Text] [Related]
19. Risk assessment in haematopoietic stem cell transplantation: minor histocompatibility antigens.
Hambach L; Spierings E; Goulmy E
Best Pract Res Clin Haematol; 2007 Jun; 20(2):171-87. PubMed ID: 17448955
[TBL] [Abstract][Full Text] [Related]
20. The allogeneic graft-versus-cancer effect.
Ringdén O; Karlsson H; Olsson R; Omazic B; Uhlin M
Br J Haematol; 2009 Dec; 147(5):614-33. PubMed ID: 19735262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
